A method and device are provided for centrifugally separating plasma from whole blood in which whole blood is introduced into a flow circuit having a blood access device connected to a first tubing for drawing whole blood from a blood source and for flowing whole blood to a centrifugal separation chamber; a volume of saline is added to the whole blood as it flows through the first tubing to dilute the whole blood; the volume of saline added to the whole blood is tracked; the whole blood having the volume of saline added thereto is separated in the centrifugal separation chamber so that an interface is created between the plasma and added saline and the cellular components of the whole blood; the separated plasma and added saline is flowed from the centrifugal separation chamber to a collection container; and a volume for the plasma and added saline in the collection container is determined. The device includes a programmable controller configured operate a first pump to flow saline from the container of saline through the second tubing segment to the first tubing segment, track a volume of saline flowed from the container of saline through the second tubing segment to the first tubing segment, flow separated plasma and added saline from the separation chamber through the third tubing segment to the collection container, and determine a volume for the plasma and added saline in the collection container.

Described is a method for controlling fluid volume balance. A controller is configured with a first set of inputs comprising a hematocrit, a total blood volume, and an ACD ratio. A maximum extracorporeal RBC amount during the procedure is estimated based on the first set of inputs. A fluid circuit is primed with a priming fluid. Whole blood is drawn from a blood source and separated into a RBC component, a target cell component, and a plasma component. The target cell component is directed to a product container. The product container comprising the target cell component is treated. A treated target cell component, a portion of the RBC component remaining in the fluid circuit, and/or a portion of the plasma component remaining in the fluid circuit are returned to the blood source. A first response action is provided if the maximum extracorporeal RBC amount estimated is above a programmed limit.

Described is a method for controlling fluid volume balance. A controller is configured with a first set of inputs comprising a hematocrit, a total blood volume, and an ACD ratio. A maximum extracorporeal RBC amount during the procedure is estimated based on the first set of inputs. A fluid circuit is primed with a priming fluid. Whole blood is drawn from a blood source and separated into a RBC component, a target cell component, and a plasma component. The target cell component is directed to a product container. The product container comprising the target cell component is treated. A treated target cell component, a portion of the RBC component remaining in the fluid circuit, and/or a portion of the plasma component remaining in the fluid circuit are returned to the blood source. A first response action is provided if the maximum extracorporeal RBC amount estimated is above a programmed limit.

Methods for monitoring patient parameters and blood fluid removal system parameters include identifying those system parameters that result in improved patient parameters or in worsened patient parameters. By comparing the patient's past responses to system parameters or changes in system parameters, a blood fluid removal system may be able to avoid future use of parameters that may harm the patient and may be able to learn which parameters are likely to be most effective in treating the patient in a blood fluid removal session.

Embodiments of the disclosure provide a method for evaluating dialyzers used in different medical applications (e.g., hemodialysis). Red blood cell volume lost in a dialyzer is monitored by obtaining blood flowrate measurements and hematocrit measurements at input ports and output ports of the dialyzer. The flowrate and hematocrit measurements are used to determine an accumulation of red cell blood volume in the dialyzer. The measurements may be obtained in a lab environment with an in-vitro blood source or may be obtained in a clinical setting with an in-vivo blood source from a patient.

A device for the continuous monitoring of blood characteristic quantities in an external cardiovascular supporting circuit, said circuit including a venous line which conveys blood from the patient to an oxygenator, and along which at least one pump is arranged, and an arterial line which returns blood from the oxygenator to the patient, where said oxygenator comprises at least one blood inlet port connected to said venous line and at least one blood outlet port connected to said arterial line, at least one inlet channel and at least one outlet channel of a work gas intended to supply oxygen to the blood and/or to remove carbon dioxide from the same.

A patient monitoring system may be used with catheters to monitor the infusion and drainage of any solution into the human body. The system may be used, for example, with in-dwelling catheters for peritoneal dialysis in end stage renal disease (ESRD) patients, urinary tract catheters, insulin pumps in diabetic patients, feeding tubes and central venous line catheters. The patient monitoring system includes one or more fluid pathways for infusing into and/or draining solutions out of the catheter, and one or more sensors to monitor the fluid. The patient monitoring system transmits the patient monitoring data to a database, allowing data storage, processing, and access through graphical user interfaces to patients and providers via device applications or browser-based web access portals.

A system for calculating cardiac output of a patient on an extracorporeal blood oxygenation circuit, such as veno-venous extracorporeal membrane oxygenation, includes determining (i) a first arterial carbon dioxide content or surrogate and (ii) a first carbon dioxide content or surrogate in the blood delivered to the patient after passing the oxygenator corresponding to the first removal rate of carbon dioxide from the blood; establishing a second removal rate of carbon dioxide from the blood in the oxygenator in the extracorporeal blood oxygenation circuit; determining (i) a second arterial carbon dioxide content or surrogate and (ii) a second carbon dioxide content or surrogate in the blood delivered to the patient after passing the oxygenator corresponding to the second removal rate of carbon dioxide from the blood; and calculating a cardiac output of the patient corresponding to a blood flow rate through the extracorporeal blood oxygenation circuit, the first arterial carbon dioxide content or surrogate, the first carbon dioxide content or surrogate in the blood delivered to the patient after passing the oxygenator corresponding to the first removal rate of carbon dioxide from the blood; the second arterial carbon dioxide content or surrogate and the second carbon dioxide content or surrogate in the blood delivered to the patient after passing the oxygenator corresponding to the second removal rate of carbon dioxide from the blood.

A method for adjustment of a dialysate during dialysis for a patient is provided. A patient undergoing a dialysis treatment, e.g., a hemodialysis (HD) treatment, can experience multiple physiological changes during the treatment. These can include change in blood volume as well as change in concentration of blood electrolytes. Blood electrolytes when taken out of their desired ranges can result in one or more health risks. The disclosure provides a way of avoiding those health risks by adjusting composition of dialysate during dialysis treatment such that blood electrolytes are maintained within their desired ranges.

Embodiments of the disclosure provide a method for evaluating dialyzers used in different medical applications (e.g., hemodialysis). Red blood cell volume lost in a dialyzer is monitored by obtaining blood flowrate measurements and hematocrit measurements at input ports and output ports of the dialyzer. The flowrate and hematocrit measurements are used to determine an accumulation of red cell blood volume in the dialyzer. The measurements may be obtained in a lab environment with an in-vitro blood source or may be obtained in a clinical setting with an in-vivo blood source from a patient.